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We undertook this study to evaluate whether use of tricyclic antidepressants, overall and grouped by duration, dose, recency, and type, is associated with an increased risk of NHL. We also investigated whether the association, if any, differs across the following more common types of NHL: diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and the plasma cell neoplasms (PCN), multiple myeloma (MM) and plasma cell leukemia (PCL). (Figure 1 )
Methods:
This study was conducted among enrollees at Group Health Cooperative (Group Health), a consumer-governed, non-profit health system in Washington state and Northern Idaho. Group Health currently provides health coverage to more than 650,000
enrollees; there were approximately 300,000 enrollees at the start of the study period. 17 To select cases, we first identified all persons who had been diagnosed with NHL between January 1, 1980 and March 31, 2011 at ≥25 years of age, who were enrolled for ≥2 years before diagnosis, and who resided in one of the 13 counties included in the western Washington Surveillance Epidemiology and End Results (SEER) registry at the time of diagnosis. The date of the case's diagnosis served as the reference date. We matched eight controls to each case on age (±24 months), sex, and length of enrollment at Group Health prior to the reference date, and after the start of the pharmacy database in 1977. Controls were selected to have equal or slightly longer "exposure ascertainment periods" compared to their matched case. Any exposure ascertainment periods which were longer than that of the case were then truncated to achieve equal length for all subjects within a given set. We also matched on the case's enrollment status on the reference date; Group Health members are either enrolled in integrated group practice (IGP), in which Group Health is the primary provider, or non-IGP. Controls were sampled from the defined population of Group Health enrollees. Control selection for each case was based on eligibility up until that case's reference date, and not after; thus, controls could also become cases if they were later diagnosed with NHL.
Cancer diagnoses were ascertained using Group Health automated records with linkage to the SEER registry. 18 We identified NHL cases using all ICD-O-3 histology codes for NHL in the SEER registry, according to the most recent World Health Organization (WHO) NHL classification system. 19 Common subtypes of NHL ( Figure 1) were identified using the ICD-O-3 codes specified in Table 1 29 In the absence of any conventional equivalency conversions for dosages across TCA types, we defined ≥50 mg/day as a "high" dose for all but two TCAs; 25 and 7.5 mg/day of nortriptyline and protriptyline, respectively, were defined as high dose. 14 We calculated cumulative dose as the average (standardized) daily dose times the total number of prescriptions filled, and defined low cumulative dose as ≤1,000 mgprescriptions and high cumulative dose as >1,000 mg-prescriptions (Table 2) .
We collected prescription data on opioids which have been shown to have immunosuppressive properties, including codeine, methadone, morphine and fentanyl, 30 as a potential confounder, because they are likely associated with both TCA use and risk of NHL. We collected data on prior use of selective serotonin reuptake inhibitors (SSRIs) in a manner similar to that for TCAs. In order to gauge the potential for confounding by depression, we compared the association between TCA use and NHL to that between SSRI use and NHL. Because previous studies of the relationship between SSRIs and NHL have not observed any such evidence, 10 an association between NHL risk and TCA use, but not SSRI use, would suggest that depression did not confound the results.
We used conditional logistic regression to calculate ORs and 95% CIs, implicitly adjusting for age, calendar time (the reference date), sex, and length of "exposure ascertainment period" through the matching process. We explicitly adjusted for a history of immunosuppressive opioid use. We repeated analyses separately for long-term and high-dose use of TCAs, recency of last use, and for the more common types of TCAs (Table 2 ). Our primary analysis included people for whom we had pharmacy information for as few as 2 years, as the association between use of TCAs and NHL risk could potentially have a short induction-latency period. However, we restricted some analyses to subjects for whom we had ≥5 years and ≥10 years of pharmacy data, which included >75% and 50% of study subjects, respectively. We adjusted for race in some analyses; race data were available on 99% of cases (from the SEER registry) and 65% of controls, and >99% of matched sets included at least one control with known race.
We conducted similar analyses for the more common types of NHL: cases were limited to those with the subtype of NHL in question, and controls were limited to subjects matched to those cases. We used conditional logistic regression to estimate ORs and 95% CIs of the risk of each NHL subtype in association with TCA ever-use;
additional analyses specifically investigated ORs associated with long-term use and use of high-dose TCAs, as well as recency of use and TCA type.
Results:
Our study population included 2,768 cases and 22,127 matched controls, which had similar distributions of the matching factors (Table 3) . Fifteen percent of cases had filled ≥2 TCA prescriptions and 7% had filled ≥10 prescriptions prior to the reference date, compared to 13% and 5% of controls, respectively. (Table 4 that ended more than 5 years prior to the reference date (OR: 0.9; 95% CI: 0.6-1.5; Table   4 ). The various types of TCAs did not appear to be associated with an elevated risk of NHL with the possible exception of amitriptyline (RR=1.2; 95% CI 1.0-1.4). TCA use was not associated with the individual types of NHL, with the possible exception of CLL/SLL, which was associated with longer-term TCA use (OR: 1.5; 95% CI: 1.1-2.0; Table 5 ).
In analyses adjusted for race, results were unchanged (not shown). In analyses of the association between NHL and very recent TCA use, defined as any use within 2 years of the reference date, we observed some evidence of an association with NHL risk (OR 1.3; 95% CI 1.1-1.6; Table 4 ). Low-dose rather than high-dose use appeared to account for the observed association with very recent use (low-dose users: OR 1.5 95% CI 1.1-2.1;
high-dose users: OR 1.3, 95% CI 0.7-2.4; not shown).
In analyses limited to subjects with at least 5 years of pharmacy data (i.e. those enrolled for at least 5 years after the pharmacy database began and before the reference date), ORs ranged from 1.0 to 1.3, with 95% CIs which included the null (1.0), for all patterns of TCA use (e.g. ever-use, high-dose use, TCA type) with the exception of very recent use (OR 1.3, 95% CI 1.1-1.7). For analyses limited to subjects with at least 10 years of pharmacy data, all associations with NHL were weak or absent, with the possible exception of an increased risk among users of nortriptyline (OR 1.4; 95% CI 1.0-1.9; Table 6 )).
After adjustment for race and immunosuppressive opioid use, we observed a modest increased risk of NHL among users of SSRIs, one very similar in magnitude to that seen among users of TCAs (Table 7) .
Discussion:
We did not observe an appreciably increased risk of NHL among persons who had used TCAs, even among those with a high average daily dose, high cumulative dose, or long duration of use. We observed little evidence for an elevated risk of the separate major types of NHL among persons with a history of TCA use, with the possible exception of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), for which longer-term TCA use was associated with a 50% higher risk.
We are aware of two previous studies which investigated this question. A study conducted in Denmark 10 reported a 50% higher risk of NHL risk associated with prior TCA use; this risk more than doubled with longer-term use. Similar to our study, this study used automated records to ascertain TCA use, NHL diagnoses, and potential confounders for all subjects in a defined population. Unlike our study, this study adjusted for a history of immune conditions and medications, whereas we chose to exclude subjects with immune conditions and medications in order to improve our ability to detect an association. Our reasoning was that, if TCA use did in fact increase the risk of NHLs on a relative scale, the degree to which it did so might be greatest in persons who did not have other strong risk factors. This difference could potentially account for differences in findings, if only persons with underlying immune dysfunction are susceptible to the potential effects of TCA use on lymphoma risk. However, it seems unlikely that the small portion of subjects we excluded with a history of immune disorder would so fully account for whatever underlying immune dysfunction enhances the effect of TCA use on NHL risk as to explain the large difference in risk estimates between that study and ours. A part of the difference could have been due to the fact that the Danish study adjusted for age using 10-year age categories, which could have led to residual confounding by age, as older age is positively associated with both NHL risk and history of TCA use. Finally, the RRs from that study, both for ever-use and for longer-term use, were based on relatively small numbers of exposed cases (18 and 13, respectively).
Another study of the association between TCA use and NHL risk was conducted in Canada, 11 and used population-based cancer registries and self-reported use of TCAs.
This study observed a more modest association than the Danish study for long-term use, defined as ≥25 months, versus no use (OR 1.6, 95% CI 0.8-3.3), and no evidence for an association with ever-use, defined as ≥2 weeks (OR 0.8, 95% CI 0.5-1.3). This study recruited participants and collected exposure data via mailed questionnaires; it has been shown that self-reported antidepressant use in particular tends to be underreported. 31 Non-differential underreporting by cases and controls would be expected to attenuate an association. It is plausible, however, that cases would be more likely to recall and/or report prior use of medications due to their diagnosis; this would be expected to inflate the strength of the association, which could explain an observed elevation in risk. This study did not have data on dose, or detailed data on TCA type. Because the three studies were conducted in different countries, the types of TCAs in use differed to some extent.
TCAs have been shown to be potent H1 antihistamines; amitriptyline and doxepin are among the most potent H1 antihistamines known. 32, 33 We are aware of only one epidemiologic study of the relationship between use of H1 antihistamines and the occurrence of NHL. 4 In this large prospective cohort study, current, longer-term use of H1 antihistamines (≥6 years) was associated with an increased risk of NHL overall (RR = Another possible mechanism may involve the intracellular histamine receptor, HIC. H1
antihistamines bind to HIC, stimulating it to upregulate lymphocyte mitogenesis. 35 HIC is also thought to promote the growth of transformed lymphocytes by inhibiting normal lymphocyte proliferation, which decreases suppressor T-lymphocyte function. 36, 37 Based on these findings, it seems that if antihistamines do influence lymphoma risk, the mechanism(s) by which they do so could include effects on either the early stages of lymphomagenesis, on later stages as a promoter, or both.
One strength of the present study is the use of pre-existing administrative data on TCA use, including detailed information on type, timing, and dose, which were recorded on cases and controls prior to the reference date. These data were available for both cases and controls, which reduces the potential for information bias, and eliminates concern for recall bias. The selection of cases and controls from the defined population of Group Health members avoids the problem of incomplete participation, as all data were collected directly from existing administrative records on both cases and controls, and every subject identified as a potential case or control thus was included in the study.
One possible limitation is our inability to ascertain use of TCAs that occurred prior to a subject's enrollment at Group Health or before the start of the pharmacy database in 1977. However, the Group Health population is relatively stable, and 50% of subjects had more than 10 years of pharmacy data available (i.e. they were enrolled for more than 10 years after 1977 and before the reference date). Another potential limitation is that ICD-O codes have undergone multiple revisions since 1980, and the latest classification system may still not capture the most etiologically relevant NHL subgroups. However, most changes in coding have involved rarer subtypes, while common types have remained relatively stable. In one study, 84-89% of ICD-O codes assigned between 1988-1994 were found to be correctly converted to ICD-O-3 codes for the most common NHL subtypes. 38 Further, previous studies have shown important differences in the pattern of incidence among NHL subgroups using ICD-O-3 codes, 4 so this system likely captures an important portion of etiologic variability across separate types of NHL. Finally, there is the possibility for confounding by indication; TCAs are prescribed for pain and sleep disorders, which we were unable to ascertain, and for depression, which we also were not able to ascertain with any sensitivity from the records available to the study. The presence of a weak association between SSRI use and NHL risk similar in size to that between use of TCAs and NHL argues that a small amount of confounding by depression could have been present.
The results of this study do not support the hypothesis that use of TCAs influences the risk of NHL as a whole. Subsequent studies of this question, ones that are able to separate cases according to individual types of NHL, will be useful in determining whether our observation of a 50% increase in risk of CLL/SLL is the result of anything other than chance. Table 1 . ICD-O-3 codes to identify common types of NHL. a standardized by type b range: 10 to 21,109 mg-days (90% are < 1220 mg-days) c all use on record occurred ≥5 y before reference date d any use on record occurred <5 y before reference date e any use on record occurred <2 y before reference date f odds ratios with 95% confidence intervals, adjusted for prior use of immunosuppressive opioids and for matching factors: age, sex, date of case's diagnosis, and length of enrollment prior to diagnosis, and limited to persons with ≥5 and ≥10 years of pharmacy data available, respectively 
